CN103814021B - 二氢喹啉‑2‑酮衍生物 - Google Patents

二氢喹啉‑2‑酮衍生物 Download PDF

Info

Publication number
CN103814021B
CN103814021B CN201280045041.1A CN201280045041A CN103814021B CN 103814021 B CN103814021 B CN 103814021B CN 201280045041 A CN201280045041 A CN 201280045041A CN 103814021 B CN103814021 B CN 103814021B
Authority
CN
China
Prior art keywords
methyl
quinoline
pyridin
oxo
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280045041.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103814021A (zh
Inventor
约翰尼斯·埃比
库尔特·阿姆雷因
佰努瓦·霍恩斯普格
亨纳·努斯特
伯德·库茵
刘永福
汉斯·P·梅尔基
亚历山大·V·迈韦格
彼得·莫尔
谭雪菲
周明伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201280045041.1A priority Critical patent/CN103814021B/zh
Publication of CN103814021A publication Critical patent/CN103814021A/zh
Application granted granted Critical
Publication of CN103814021B publication Critical patent/CN103814021B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201280045041.1A 2011-09-15 2012-09-12 二氢喹啉‑2‑酮衍生物 Active CN103814021B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280045041.1A CN103814021B (zh) 2011-09-15 2012-09-12 二氢喹啉‑2‑酮衍生物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2011079673 2011-09-15
CNPCT/CN2011/079673 2011-09-15
CN201280045041.1A CN103814021B (zh) 2011-09-15 2012-09-12 二氢喹啉‑2‑酮衍生物
PCT/EP2012/067744 WO2013037779A1 (fr) 2011-09-15 2012-09-12 Nouveaux dérivés de dihydroquinoline-2-one

Publications (2)

Publication Number Publication Date
CN103814021A CN103814021A (zh) 2014-05-21
CN103814021B true CN103814021B (zh) 2016-12-21

Family

ID=46829775

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280045041.1A Active CN103814021B (zh) 2011-09-15 2012-09-12 二氢喹啉‑2‑酮衍生物

Country Status (32)

Country Link
US (1) US9260408B2 (fr)
EP (2) EP3653618A1 (fr)
JP (1) JP6012735B2 (fr)
KR (1) KR101785143B1 (fr)
CN (1) CN103814021B (fr)
AR (1) AR087901A1 (fr)
AU (1) AU2012307509B2 (fr)
BR (1) BR112014006283B1 (fr)
CA (1) CA2846785C (fr)
CL (1) CL2014000604A1 (fr)
CO (1) CO6890099A2 (fr)
CR (1) CR20140091A (fr)
DK (1) DK2755963T3 (fr)
EA (1) EA035757B1 (fr)
EC (1) ECSP14013245A (fr)
ES (1) ES2763332T3 (fr)
HR (1) HRP20192323T1 (fr)
HU (1) HUE047771T2 (fr)
IL (1) IL231229A0 (fr)
LT (1) LT2755963T (fr)
MX (1) MX358376B (fr)
MY (1) MY169043A (fr)
PE (1) PE20141372A1 (fr)
PL (1) PL2755963T3 (fr)
PT (1) PT2755963T (fr)
RS (1) RS59737B1 (fr)
SG (1) SG11201400679WA (fr)
SI (1) SI2755963T1 (fr)
TW (1) TWI462914B (fr)
UA (1) UA111626C2 (fr)
WO (1) WO2013037779A1 (fr)
ZA (1) ZA201401884B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2964628B1 (fr) * 2013-03-08 2019-09-11 F.Hoffmann-La Roche Ag Nouveaux dérivés de dihydroquinoline-2-one en tant qu'inhibiteurs d'aldostérone synthase (cyp1 1 b2 ou cyp1 1 b1)
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
CN105073732B (zh) * 2013-03-14 2017-07-21 豪夫迈·罗氏有限公司 用作醛固酮合酶抑制剂的二氢喹啉‑2‑酮衍生物
MX2015011005A (es) 2013-03-14 2015-10-22 Hoffmann La Roche Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.
JP6067181B2 (ja) * 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
SI3004077T1 (sl) * 2013-05-27 2020-01-31 F. Hoffmann-La Roche Ag Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on
LT3004076T (lt) * 2013-05-27 2020-01-10 F. Hoffmann-La Roche Ag Nauji 3,4-dihidro-2h-izochinolin-1-ono ir 2,3-dihidro-izoindol-1-ono junginiai
EP3004089B1 (fr) * 2013-05-27 2020-05-06 F.Hoffmann-La Roche Ag Nouveaux composés 3,4-dihydro-2h-isoquinoline-1-one et 2,3-dihydro-iso-indol-1-one
WO2015125858A1 (fr) * 2014-02-24 2015-08-27 日本曹達株式会社 Composé hétéro-aryle et ses applications
US20170190705A1 (en) * 2014-03-26 2017-07-06 The Brigham And Woman's Hospital, Inc. Compositions and Methods for Inhibiting BMP
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
CN106604917B (zh) * 2014-10-31 2020-10-09 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物
JP6622300B2 (ja) * 2014-10-31 2019-12-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規なジヒドロキノリンピラゾリル化合物
CN106660998B (zh) * 2014-10-31 2019-10-25 豪夫迈·罗氏有限公司 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂
AU2016317806B2 (en) 2015-08-31 2020-11-19 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
JP6314196B2 (ja) * 2015-10-22 2018-04-18 田辺三菱製薬株式会社 医薬組成物
WO2017069226A1 (fr) * 2015-10-23 2017-04-27 田辺三菱製薬株式会社 Nouveau composé hétérocyclique aromatique contenant de l'azote
US10913730B2 (en) 2016-10-10 2021-02-09 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as Mer inhibitors
CR20190268A (es) * 2016-12-08 2019-07-11 Hoffmann La Roche Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
JP2022530775A (ja) 2019-05-01 2022-07-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート
WO2023063851A1 (fr) * 2021-10-13 2023-04-20 «Target Medicals» Limited Liability Company Inhibiteurs de l'aldostérone synthase humaine (cyp11b2)
WO2024102026A1 (fr) * 2022-11-10 2024-05-16 «Target Medicals» Limited Liability Company Inhibiteurs de l'aldostérone synthase humaine (cyp11b2)
WO2024109885A1 (fr) * 2022-11-23 2024-05-30 上海翰森生物医药科技有限公司 Inhibiteur de composé polycyclique de pyridine, son procédé de préparation et son utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85100796A (zh) * 1985-04-01 1986-10-01 辉瑞公司 喹啉酮衍生物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334282D0 (en) * 1983-12-22 1984-02-01 Pfizer Ltd Quinolone inotropic agents
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
FR2580646A1 (fr) * 1985-04-19 1986-10-24 Synthelabo Derives de 2(1h)-quinolinone, leur preparation et leur application en therapeutique
WO2006113432A2 (fr) 2005-04-14 2006-10-26 Smithkline Beecham Corporation Composes, compositions et procedes
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
MX2011012199A (es) 2009-05-15 2011-12-08 Novartis Ag Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
WO2010130796A1 (fr) 2009-05-15 2010-11-18 Novartis Ag Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85100796A (zh) * 1985-04-01 1986-10-01 辉瑞公司 喹啉酮衍生物的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fine-Tuning the Selectivity of Aldosterone Synthase Inhibitors:Structure-Activity and Structure-Selectivity Insights from Studies of Heteroaryl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4- one Derivatives;Simon Lucas et al.;《J. Med. Chem.》;20110308;第54卷;第2307-2319页 *

Also Published As

Publication number Publication date
SI2755963T1 (sl) 2020-01-31
TW201315724A (zh) 2013-04-16
BR112014006283A2 (pt) 2017-04-11
PE20141372A1 (es) 2014-10-13
UA111626C2 (uk) 2016-05-25
WO2013037779A1 (fr) 2013-03-21
DK2755963T3 (da) 2020-01-13
CO6890099A2 (es) 2014-03-10
JP2014527077A (ja) 2014-10-09
CA2846785C (fr) 2020-09-22
EP2755963B1 (fr) 2019-10-30
BR112014006283B1 (pt) 2021-11-03
CA2846785A1 (fr) 2013-03-21
CN103814021A (zh) 2014-05-21
PT2755963T (pt) 2020-01-10
AR087901A1 (es) 2014-04-23
ECSP14013245A (es) 2014-07-31
KR101785143B1 (ko) 2017-10-12
PL2755963T3 (pl) 2020-07-27
TWI462914B (zh) 2014-12-01
EA035757B1 (ru) 2020-08-05
KR20140067121A (ko) 2014-06-03
NZ621599A (en) 2016-07-29
CL2014000604A1 (es) 2014-10-17
EA201490596A1 (ru) 2014-07-30
MX2014002770A (es) 2014-06-05
EP2755963A1 (fr) 2014-07-23
AU2012307509B2 (en) 2017-06-29
ZA201401884B (en) 2019-11-27
IL231229A0 (en) 2014-04-30
MX358376B (es) 2018-08-16
ES2763332T3 (es) 2020-05-28
US20130072679A1 (en) 2013-03-21
SG11201400679WA (en) 2014-04-28
RS59737B1 (sr) 2020-02-28
EP3653618A1 (fr) 2020-05-20
HRP20192323T1 (hr) 2020-03-20
JP6012735B2 (ja) 2016-10-25
LT2755963T (lt) 2020-01-27
MY169043A (en) 2019-02-07
AU2012307509A1 (en) 2014-03-13
US9260408B2 (en) 2016-02-16
CR20140091A (es) 2014-06-03
HUE047771T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
CN103814021B (zh) 二氢喹啉‑2‑酮衍生物
CN103827101B (zh) 双环二氢喹啉-2-酮衍生物
CN104684915B (zh) 新型双环衍生物
CN103254190B (zh) 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2，3-b]吡啶和吡咯并[2，3-b]嘧啶
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN105085489B (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
CN105924437B (zh) 作为iii型受体酪氨酸激酶抑制剂的化合物
CN105764905B (zh) 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
CN102365020B (zh) 哒嗪酮化合物
CN106852142A (zh) 作为醛固酮合酶抑制剂的螺二胺衍生物
CN111902415A (zh) 药学化合物
CN108473502A (zh) 用于治疗癌症的4,6二氢吡咯并[3,4-c]吡唑-5(1h)-腈衍生物
CN108617166A (zh) 蛋白激酶抑制剂苯并内酰胺化合物
CN108473468A (zh) Ret的抑制剂
CN101801383A (zh) 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂
CN105916856A (zh) 作为酪蛋白激酶1d/e抑制剂的取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物
CN101506165A (zh) 苯基、吡啶和喹啉衍生物
CN105209468A (zh) 取代的7-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN104736533B (zh) Vegfr3抑制剂
CN106164076A (zh) 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
CN109689645A (zh) 作为nik抑制剂的氰基吲哚啉衍生物
CN107438598A (zh) 喹唑啉和喹啉化合物及其用途
CN105308045B (zh) 新的3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物
CN103958478B (zh) 双环二氢异喹啉‑1‑酮衍生物
CN105143204B (zh) 3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1195766

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1195766

Country of ref document: HK